Physics and AI Driven Precision Engineering of Novel Drugs
Health + Time : Priceless
We Engineer New Treatments Atom by Atom
To help you live healthier, longer
Your browser does not support the video tag.
For a range of major human diseases, we’re developing treatments that cannot be found through any other method
For a range of major human diseases, we’re developing treatments that cannot be found through any other method
Your browser does not support the video tag.
First-in-Class Drug Candidates
to Change the Standard of Care for Every Disease We Address
PREVENTING HEART ATTACKS & STROKES WITH LOWER BLEEDING RISK
to help
185.7M
patients
2 Candidates
VE-1902, VE-2851
Stage: Clinical
PREVENTING & TREATING DIABETIC VISION LOSS WITHOUT EYE INJECTIONS
to help
179M
patients
2 Candidates
VE-4840, VE-3539
Stage: IND-Prep
PROVIDING CHEMO AGENTS FOR MULTIDRUG-RESISTANT CANCERS
to help
10M
patients
2 Candidates
VE-4054, VE-4932
Stage: Preclinical
PREVENTING AGGRESSIVE SOLID-TUMOR CANCER METASTASIS
to help
9M
patients
2 Candidates
VE-2843, VE-1787
Stage: Optimization
RESTORING IMMUNE RESPONE TO CD73 POSITIVE CANCERS
to help
6.5M
patients
2 Candidates
VE-3771, VE-5953
Stage: Preclinical
+
Many More…
Previous
Next
More about our pipeline
Recent News
First-in-Class Drug Candidates
to Change the Standard of Care for Every Disease We Address
PREVENTING HEART ATTACKS & STROKES WITH LOWER BLEEDING RISK
to help
185.7M
patients
2 Candidates
VE-1902, VE-2851
Stage: Clinical
PREVENTING & TREATING DIABETIC VISION LOSS WITHOUT EYE INJECTIONS
to help
179M
patients
2 Candidates
VE-4840, VE-3539
Stage: IND-Prep
PROVIDING CHEMO AGENTS FOR MULTIDRUG-RESISTANT CANCERS
to help
10M
patients
2 Candidates
VE-4054, VE-4932
Stage: Preclinical
PREVENTING AGGRESSIVE SOLID-TUMOR CANCER METASTASIS
to help
9M
patients
2 Candidates
VE-2843, VE-1787
Stage: Optimization
RESTORING IMMUNE RESPONE TO CD73 POSITIVE CANCERS
to help
6.5M
patients
2 Candidates
VE-3771, VE-5953
Stage: Preclinical
+
Many More…
Previous
Next
More about our pipeline
Recent News
Our stories
Nobel Laureate Hartmut Michel Joins Verseon's Scientific Advisory Board
Pioneering expert in membrane protein structure and function to advise Verseon on its platform and pipeline development
November 9, 2023
California-based Verseon is Spearheading the New approach to Drug Development
The emergence of completely new drugs to tackle some of the world’s most prevalent diseases have been few and far between. But that could be about to change. Verseon creates drugs atom by atom, using a proprietary technology platform that goes far beyond just the application of AI
September 15, 2023
Faster, better, more productive
[Verseon’s] models for “de novo molecular design” can figure out which molecular structures are most likely to do which things, and they build accordingly
September 13, 2023
Digital CxO Podcast Ep. 50 - AI for the Pharmaceutical Industry
Verseon is changing how completely new medicines get designed, what we can treat and how well we treat them.... The company designs, atom by atom, completely novel drugs that you cannot find with any other method.... They hold the promise of completely changing the standard of care for the diseases they address because of how unique their therapeutic profiles are
July 24, 2023
Why AI alone won't resolve drug discovery challenges
"When it comes to drug discovery, AI has a data problem with which the pharmaceutical industry has not yet come to terms"
June 21, 2023
Exploring New Chemical Space for the Treatments of Tomorrow
We've seen the benefits of exploring entirely novel chemical entities... We are now entering an exciting new era in drug discovery and development with immense implications for human health.
June 1, 2023
AI in drug development: A reality check
"Existing data... is a small, little tiny pittance compared to the total number of possibilities that one could explore... Asking A.I. trained on that data to suddenly change everything... is more than just asking a lot. It's not possible."
May 25, 2023
Unlocking a Universe of Drug Candidates
Verseon's hybrid physics- and AI-based platform reveals possibilities far outside the Pharma industry's compound libraries
May 4, 2023
Nobel Laureate Hartmut Michel Joins Verseon's Scientific Advisory Board
Pioneering expert in membrane protein structure and function to advise Verseon on its platform and pipeline development
November 9, 2023
California-based Verseon is Spearheading the New approach to Drug Development
The emergence of completely new drugs to tackle some of the world’s most prevalent diseases have been few and far between. But that could be about to change. Verseon creates drugs atom by atom, using a proprietary technology platform that goes far beyond just the application of AI
September 15, 2023
Faster, better, more productive
[Verseon’s] models for “de novo molecular design” can figure out which molecular structures are most likely to do which things, and they build accordingly
September 13, 2023
Digital CxO Podcast Ep. 50 - AI for the Pharmaceutical Industry
Verseon is changing how completely new medicines get designed, what we can treat and how well we treat them.... The company designs, atom by atom, completely novel drugs that you cannot find with any other method.... They hold the promise of completely changing the standard of care for the diseases they address because of how unique their therapeutic profiles are
July 24, 2023
Why AI alone won't resolve drug discovery challenges
"When it comes to drug discovery, AI has a data problem with which the pharmaceutical industry has not yet come to terms"
June 21, 2023
Exploring New Chemical Space for the Treatments of Tomorrow
We've seen the benefits of exploring entirely novel chemical entities... We are now entering an exciting new era in drug discovery and development with immense implications for human health.
June 1, 2023
AI in drug development: A reality check
"Existing data... is a small, little tiny pittance compared to the total number of possibilities that one could explore... Asking A.I. trained on that data to suddenly change everything... is more than just asking a lot. It's not possible."
May 25, 2023
Unlocking a Universe of Drug Candidates
Verseon's hybrid physics- and AI-based platform reveals possibilities far outside the Pharma industry's compound libraries
May 4, 2023
More News
Our stories
Nobel Laureate Hartmut Michel Joins Verseon's Scientific Advisory Board
Pioneering expert in membrane protein structure and function to advise Verseon on its platform and pipeline development
November 9, 2023
California-based Verseon is Spearheading the New approach to Drug Development
The emergence of completely new drugs to tackle some of the world’s most prevalent diseases have been few and far between. But that could be about to change. Verseon creates drugs atom by atom, using a proprietary technology platform that goes far beyond just the application of AI
September 15, 2023
Faster, better, more productive
[Verseon’s] models for “de novo molecular design” can figure out which molecular structures are most likely to do which things, and they build accordingly
September 13, 2023
Digital CxO Podcast Ep. 50 - AI for the Pharmaceutical Industry
Verseon is changing how completely new medicines get designed, what we can treat and how well we treat them.... The company designs, atom by atom, completely novel drugs that you cannot find with any other method.... They hold the promise of completely changing the standard of care for the diseases they address because of how unique their therapeutic profiles are
July 24, 2023
More News
Changing everything the world can expect from 21st Century Medicine
Continue to
Company
Your browser does not support the video tag.